- Community-Beiträge
- Aktuellste Threads
| Geld/Brief | 20,58 € / 20,72 € |
| Spread | +0,68% |
| Schluss Vortag | 20,43 € |
| Gehandelte Stücke | 150 |
| Tagesvolumen Vortag | 42.541,36 € |
| Tagestief 20,40 € Tageshoch 20,40 € | |
| 52W-Tief 16,41 € 52W-Hoch 24,37 € | |
| Jahrestief 19,005 € Jahreshoch 21,67 € | |
| Umsatz in Mio. | 491,73 $ |
| Operatives Ergebnis (EBIT) in Mio. | 195,12 $ |
| Jahresüberschuss in Mio. | 163,89 $ |
| Umsatz je Aktie | 3,89 $ |
| Gewinn je Aktie | 1,30 $ |
| Gewinnrendite | +22,52% |
| Umsatzrendite | +33,33% |
| Return on Investment | +19,25% |
| Marktkapitalisierung in Mio. | 2.635 $ |
| KGV (Kurs/Gewinn) | 16,05 |
| KBV (Kurs/Buchwert) | 3,62 |
| KUV (Kurs/Umsatz) | 5,37 |
| Eigenkapitalrendite | +22,52% |
| Eigenkapitalquote | +85,46% |
| Faktor-Zertifikate | 6 | |
| Knock-Outs | 3 |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Düsseldorf | 19,95 € | +1,58% | 19,64 € | 12:31 | |
| Frankfurt | 20,39 € | +6,64% | 19,12 € | 12:53 | |
| Hamburg | 19,86 € | +3,87% | 19,12 € | 08:17 | |
| München | 19,99 € | +1,39% | 19,716 € | 08:01 | |
| Stuttgart | 20,61 € | +1,23% | 20,36 € | 17:31 | |
| L&S RT | 20,65 € | +1,08% | 20,43 € | 17:55 | |
| NYSE | 23,93 $ | +4,04% | 23,00 $ | 02.03.26 | |
| Nasdaq | 23,88 $ | +3,49% | 23,075 $ | 02.03.26 | |
| AMEX | 23,86 $ | +2,71% | 23,23 $ | 02.03.26 | |
| Tradegate | 20,40 € | -0,15% | 20,43 € | 15:33 | |
| Quotrix | 20,31 € | +3,73% | 19,58 € | 07:27 | |
| Gettex | 20,745 € | +1,87% | 20,365 € | 17:44 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 02.03.26 | 19,695 | 8.714 |
| 27.02.26 | 19,52 | 45.656 |
| 26.02.26 | 21,07 | 0 |
| 25.02.26 | 21,07 | 13.328 |
| 24.02.26 | 20,54 | 0 |
| 23.02.26 | 20,45 | 23.527 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 20,45 € | -3,69% |
| 1 Monat | 21,20 € | -7,10% |
| 6 Monate | 17,655 € | +11,55% |
| 1 Jahr | 22,06 € | -10,72% |
| 5 Jahre | 3,2715 € | +502,02% |
| Marktkapitalisierung | 3,69 Mrd. € |
| Aktienanzahl | 178,41 Mio. |
| Streubesitz | 6,81% |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
| +15,44% | BlackRock Inc |
| +7,16% | Vanguard Group Inc |
| +4,48% | State Street Corp |
| +2,66% | Renaissance Technologies Corp |
| +2,60% | Morgan Stanley - Brokerage Accounts |
| +2,35% | Deerfield Management Co |
| +2,34% | Geode Capital Management, LLC |
| +2,21% | Fundsmith LLP |
| +1,97% | Goldman Sachs Group Inc |
| +1,93% | Bank of America Corp |
| +1,56% | Dimensional Fund Advisors, Inc. |
| +1,44% | American Century Companies Inc |
| +1,29% | Royce & Associates, LP |
| +1,17% | Charles Schwab Investment Management Inc |
| +1,05% | Boston Partners Global Investors, Inc |
| +1,04% | Northern Trust Corp |
| +1,00% | Arrowstreet Capital Limited Partnership |
| +0,99% | Amvescap Plc. |
| +0,85% | Allianz Asset Management AG |
| +0,83% | Qube Research & Technologies |
| +38,82% | Weitere |
| +6,81% | Streubesitz |
Zahlen für Q3/20
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-third-quarter-2020-financial
Bundesrichter entscheidet im Sinne der FDA & Jacobus Pharmaceuticals
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-ruling-lawsuit-against-fda
Catalyst Pharma hat die Klage gegen die FDA verloren
Das könnte Ruzurgi(Amifampridin) von Jacobus Pharmaceutical bei Erwachsenen LEMS-Patienten den Weg ebnen.
https://seekingalpha.com/news/3598477-catalyst-pharma-down-13-on-adverse-ruling-in-fda-lawsuit
MuSK-MG Phase 3 Trial did not Achieve Statistical Significance for Primary or Secondary Endpoints
https://ir.catalystpharma.com/news-releases/news-release-details/catalyst-pharmaceuticals-announces-second-quarter-2020-financial
Zahlen für Q2/20
